Boehringer Ingelheim
For Healthcare Professionals
Nintedanib
Nintedanib_1

Meet John: IPF Patient Journey

14/02/2025 | Author: Boehringer Ingelheim

Document ID: PC-SG-102616

About Pulmonary Fibrosis

Meet Kim: SSc-ILD Patient Journey
Meet Daniel: RA-ILD Patient Journey
Meet John: IPF Patient Journey
A1-R101||A2-R101||How to recognize pulmonary fibrosis on HRCT scans (Rheum)
A1-R101||A2-R101||Time is of the essence: Suspect fibrotic interstitial lung disease
A1-R101||A2-R101||ILD in SSc & when to consider treatment by Dr. E. Volkmann
A1-R101||A2-R101||Risk factors for Progressive RA-ILD by Dr. E. Volkmann
A1-R101||A2-R101||Importance of MDD for managing CTD-ILD patients by Dr E. Volkmann
A1-R101||A2-R101||Identifying ILD in patients with RA by Dr. Anna Hoffman-Vold
A1-R101||A2-R101||RA-ILD DELPHI CONSENSUS SCREENING ALGORITHM
A1-R101||A2-R101||How to identify patients with RA-ILD who can benefit from OFEV
FSIN||How to recognize ILD in PPF patients with CTD
Listen to our experts share their thoughts on what PF-ILD is and the high unmet need surrounding this disease
Listen to our experts explain the importance of proactive monitoring in patients with ILD
SGOFV2023COM||Vigilance and proactivity are critical in reducing the burden of disease
SGOFV2023COM||Regular screening is critical as ILD can develop early
Risk of acute exacerbations
Lung function decline
Pathophysiology of Pulmonary Fibrosis in ILD

RELATED CONTENT